AKT1 and neoplasm: Beyond capivasertib and ipatasertib, other AKT inhibitors under development for pan-tumor indications include miransertib (NCT01473095), BAY 1125976 (NCT01915576), an AKT1/2 inhibitor, and TAS0612 (NCT04586270), which targets RSK/AKT/S6K signaling.